Technology & Platform
Richard DiMarchi is one of the world’s leading peptide chemists. He has successfully designed multiple peptide-based drugs and drug candidates. His research group is well recognized for discovery of novel chemical approaches to drug discovery and their application to the design of peptides with optimized pharmacological characteristics.
Native peptide hormones are challenging to use as drugs. By contrast, peptides designed using our chemical technology and state-of-the-art experience have significantly enhanced pharmacokinetics and pharmacodynamics relative to native sequence. Importantly, these characteristics can be fine-tuned based upon reproducible chemical strategies that have been well proven in endocrine diseases.
In the news…
MBX Biosciences today announced the appointment of Mary Jane Geiger, M.D., Ph.D, FACP, FAHA. to the newly created role of chief medical officer. Dr. Geiger will oversee MBX’s global clinical drug development, bringing more than 20 years’ experience in clinical drug development and supporting multiple successful drug registrations.
MBX Biosciences today announced the appointment of James Cornelius to its board of directors. Mr. Cornelius brings deep experience growing companies, including as chairman and CEO of Bristol Myers Squibb, and as board member and CFO of Eli Lilly.
MBX Biosciences announced today the the closing of a $34.6 million Series A financing. The financing was led by Frazier Healthcare Partners, with participation from OrbiMed, New Enterprise Associates, Indiana Philanthropic Venture Fund (IU PhV), Indiana Seed Fund III (managed by BioCrossroads) and Twilight Venture Partners II.